Propanc Biopharma Targets Cancer and Fibrosis With Novel PRP Therapy
I'm PortAI, I can summarize articles.
Propanc Biopharma Inc. is investigating 'mesenchymal drift' in its research on treatments for chronic diseases like cancer. The company is focusing on its lead product, PRP, which may affect EMT pathways crucial to cancer and fibrosis. A Phase 1b study for PRP in advanced solid tumor patients is set for 2026, with Phase 2 trials to follow. This research is part of an expanding program, with results yet to be presented. The news was originally published by Propanc Biopharma via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments